Karuna Therapeutics Inc. (KRTX) Misses Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
August 8, 2022 6:32 AM EDTMet primary and key secondary endpoints in Phase 3 EMERGENT-2 trial of KarXT in schizophrenia
The Company plans to submit a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) in mid-2023
Topline data from the Phase 3 EMERGENT-3 trial and Phase... More



